Matthew A. Lunning
马修·朗宁
DO
Associate Professor of Medicine; Hematology/Oncology医学副教授；血液/肿瘤科
👥Biography 个人简介
Dr. Matthew Lunning specializes in indolent B-cell lymphomas with a focus on follicular lymphoma. He has been at the forefront of evaluating bispecific antibodies including mosunetuzumab and epcoritamab, contributing to pivotal trials that have expanded treatment options for relapsed follicular lymphoma.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Bispecific Antibodies in Follicular Lymphoma
Contributed to early and pivotal trials of mosunetuzumab and other T-cell engaging bispecific antibodies, helping establish these agents as effective off-the-shelf immunotherapy for relapsed/refractory follicular lymphoma.
Representative Works 代表性著作
Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma
New England Journal of Medicine (2022)
Pivotal study demonstrating 80% overall response rate with mosunetuzumab in heavily pre-treated follicular lymphoma, leading to accelerated FDA approval.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Sebastian Bauer
University Hospital Essen (Universitätsklinikum Essen)
Suzanne George
Dana-Farber Cancer Institute / Harvard Medical School
Marcia S. Brose
Sidney Kimmel Cancer Center, Thomas Jefferson University
Lori J. Wirth
Massachusetts General Hospital, Harvard Medical School
关注 马修·朗宁 的研究动态
Follow Matthew A. Lunning's research updates
留下邮箱，当我们发布与 Matthew A. Lunning（University of Nebraska Medical Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment